Clinical Trial Update: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial [Phase 3]

View source ↗

Summary

Phase 3 trial update for Olpasiran targeting lipoprotein(a) reduction in cardiovascular disease; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• Olpasiran (olpasiran)

Snippet

Sponsor: Amgen | Conditions: Cardiovascular Disease | Phase 3 | Status: RECRUITING